CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
OPERATING EXPENSES
General and administrative	$ 543	$ 1,757
Research and development	1,041	1,182
Total operating expenses	1,584	2,939
Interest and other expenses (income), net	81	24
Loss from operations before taxes	1,665	2,963
Income tax benefit	(56)	(192)
Net Loss	1,609	2,771
Less: Net Loss attributable to the noncontrolling interest	(946)	0
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$ 663	$ 2,771
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutics Corp. stockholders (in dollars per share)	$ 0.02	$ 0.07
Basic and diluted shares outstanding (in shares)	40,885	40,885